VYNE News and Press, VYNE Therapeutics Inc Com From 04/19/23

VYN201 at the 0.5 mg/ml and 1 mg/ml doses demonstrated statistically significant reductions in lung fibrosis and hydroxyproline levels compared to placebo Reduction in lung fibrosis from VYN201 treatment resulted in significant improvements in blood oxygen saturation and functional lung v...

2023-03-30 10:02:34 ET Gainers: SCYNEXIS ( SCYX ) +61% . Palisade Bio ( PALI ) +33% . Biophytis ( BPTS ) +10% . RenovoRx ( RNXT ) +9% . VYNE Therapeutics ( VYNE ) +9% . Losers: AngioDynamics ( ANGO ) -28% . ...

No quantifiable VYN201 plasma concentrations above the assay lower limit of quantification supports “soft” drug approach for topical pan-BD BET inhibitor All hematological parameters, including platelet counts, were within normal ranges, a finding which has not previousl...

BRIDGEWATER, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-infl...

2023-03-09 17:02:29 ET VYNE Therapeutics press release ( NASDAQ: VYNE ): Q4 GAAP EPS of -$2.60. As of December 31, 2022, VYNE had cash and cash equivalents, and restricted cash of $31.0 million. For further details see: VYNE Therapeutics GAAP EPS of -$2.60

First vitiligo patients being treated with pan-BD BET inhibitor, VYN201, for up to 16 weeks in Phase 1b clinical trial Anticipate topline Phase 1b data in mid-2023 BRIDGEWATER, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or th...

BRIDGEWATER, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-infla...

BRIDGEWATER, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory co...

VYNE Therapeutics ( NASDAQ: VYNE ) is trading ~8% higher premarket after it announced positivedata from the Phase 1 trial testing novel BET inhibitor, VYN201, for vitiligo. The early-stage trial tested single ascending and multiple ascending doses of VYN201, which were applied to...

VYN201 was generally well-tolerated with no clinically relevant treatment emergent adverse events from all dose cohorts, meeting the primary objective of the study Topline Phase 1b results in vitiligo patients expected in mid-2023 BRIDGEWATER, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) --...